With thousands of press releases published each week, it can be difficult to keep up with everything on PR Newswire. To help ...

Quest Diagnostics has introduced a new blood test aimed at assisting physicians in confirming amyloid brain pathology related ...

Barclays analyst Luke Sergott maintained a Hold rating on Quest Diagnostics (DGX – Research Report) today and set a price target of $175.00.

The comedian Drew Lausch relayed a story about his recent hookup with a doctor (OK brag) and what the experience taught him ...

About 1,200 B.C. LifeLabs employees have been on rotating strikes since Feb. 16. On Monday, four of 10 locations in or near ...

Quest Diagnostics Inc. closed 8.28% below its 52-week high of $178.87, which the company reached on March 10th.

Mizuho raised the firm’s price target on Quest Diagnostics (DGX) to $189 from $178 and keeps an Outperform rating on the shares. The firm ...

Shares of Quest Diagnostics Inc. DGX slid 2.74% to $159.80 Tuesday, on what proved to be an all-around dismal trading session ...

The firm recently announced agreements with Labcorp and Quest Diagnostics to provide its devices for self-collection of vaginal swab specimens.

Investment analysts at Leerink Partnrs dropped their Q2 2025 earnings per share (EPS) estimates for shares of Quest ...

Genomic Testing Cooperative (GTC) is expanding into the European market by partnering with German laboratory Labor Dr.

Valued at a market cap of $18.2 billion, Quest Diagnostics Incorporated (DGX) provides diagnostic testing and services in the ...